CNA gain of EGRF was also more common in the mucinous MSS cohort compared to the adenocarcinoma NOS MSS cohort (38.5% vs. 0.0% p < 0.0001) as was CNA gain of MYC (61.5% vs. 0.0% p < 0.0001). This evidence concerns the gene MYC and adenocarcinoma.